ArticleRSC mechanochemistry2026
Identifying new solid forms of a labile pharmaceutical compound by additive assisted mechanochemistry.
Article in RSC mechanochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mechanochemical processing of labile active pharmaceutical ingredients (APIs) presents a fundamental trade-off: added solvent can accelerate solid form transformations yet may simultaneously promote chemical degradation. This study aims to explore this tension with an oxidation prone model pharmaceutical, cysteamine. Specifically, we examine the effects and interactions of antioxidant incorporation, reactant stoichiometry, ball to powder ratio (BPR), milling duration, and solvent assisted grinding on solid form screening success rates and yield. We find that the incorporation of ascorbic acid (ASC) as an antioxidant markedly improved resistance to oxidative degradation under a large set of milling conditions. Systematic variation of ASC molar ratios revealed an optimal composition at 1 : 1 : 2 (cysteamine : coformer : ASC) which reproducibly improved cysteamine recovery (90-110%,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.